Genematrix진매트릭스

Genematrix remains loss-making, with revenue roughly flat and its shares down sharply over the past year.

Genematrix sells molecular diagnostic kits and is developing vaccines and immuno-oncology treatments. Over the trailing twelve months to H1 2026 it reported revenue of about ₩10.9B, an operating loss of about ₩0.2B and a net loss of about ₩0.8B, and its shares closed at ₩1,450 on 27 October 2026, down 42.9% over one year. The company started a Phase 1 trial of a domestically developed hepatitis A vaccine on the same day.

What stands out

• Revenue has been broadly stable around ₩10–12B a year since 2021, and 2025 growth was 6.2%.
• Losses have narrowed from 2024, with the H1 2026 trailing operating margin at -2.2% versus -6.4% in 2025 and -16.4% in 2024.
• Net income was still negative in every year from 2021 to 2025, and the trailing net loss is about ₩0.8B.
• Cash of about ₩5.7B compares with borrowings of ₩3.6B, and trailing free cash flow was positive at about ₩1.2B.
• Foreign ownership fell from 2.0% to 1.7% over 60 days, and 20-day flows were net selling by foreign investors and institutions with retail buying.

What to watch

• Whether the hepatitis A vaccine Phase 1 trial progresses and what the company discloses about it.
• The nature of the 'Amended: Major management matter relevant to investors' filing dated 27 October 2026, which the data does not describe.
• Whether the company returns to positive operating income, given the valuation (P/B 1.6, EV/EBITDA 57.4) and no P/E because earnings are negative.